Literature DB >> 10430072

Doxorubicin gradients in human breast cancer.

J Lankelma1, H Dekker, F R Luque, S Luykx, K Hoekman, P van der Valk, P J van Diest, H M Pinedo.   

Abstract

Ten patients with locally advanced breast cancer were given doxorubicin i.v., and an incision biopsy was subsequently taken. Doxorubicin autofluorescence was examined using computerized laser scanning microscopy, and microvessels were immunostained in the same sections. Overlays of both pictures revealed doxorubicin gradients in tumor islets with high concentrations in the periphery and low concentrations in the center of the tumor islets. Gradients were most pronounced shortly after the injection, but they could still be detected 24 h later. No gradients were observed in connective tissue. This study demonstrates a serious risk of the drug not reaching all of the cancer cells in those cases in which the cancer cells are densely packed in islets. The efficacy of drug treatment will thus depend on the histology of the tumor tissue.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10430072

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  66 in total

Review 1.  Neoadjuvant chemoimmunotherapy in locally advanced breast cancer: a new avenue to be explored.

Authors:  Jan Buter; Herbert M Pinedo
Journal:  Curr Oncol Rep       Date:  2003-05       Impact factor: 5.075

2.  Simultaneous detection of intracellular target and off-target binding of small molecule cancer drugs at nanomolar concentrations.

Authors:  Heike Glauner; Ivo R Ruttekolk; Kerrin Hansen; Ben Steemers; Yi-Da Chung; Frank Becker; Stefan Hannus; Roland Brock
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

3.  Schedule-dependent potentiation of chemotherapy drugs by the hypoxia-activated prodrug SN30000.

Authors:  Xinjian Mao; Sarah McManaway; Jagdish K Jaiswal; Cho R Hong; William R Wilson; Kevin O Hicks
Journal:  Cancer Biol Ther       Date:  2019-05-26       Impact factor: 4.742

Review 4.  ABC transporters: unvalidated therapeutic targets in cancer and the CNS.

Authors:  Robert W Robey; Paul R Massey; Laleh Amiri-Kordestani; Susan E Bates
Journal:  Anticancer Agents Med Chem       Date:  2010-10-01       Impact factor: 2.505

5.  A new mathematical pharmacodynamic model of clonogenic cancer cell death by doxorubicin.

Authors:  Jan Lankelma; Rafael Fernández Luque; Henk Dekker; Jaap van den Berg; Bob Kooi
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-07-18       Impact factor: 2.745

Review 6.  Extracellularly activatable nanocarriers for drug delivery to tumors.

Authors:  Sara A Abouelmagd; Hyesun Hyun; Yoon Yeo
Journal:  Expert Opin Drug Deliv       Date:  2014-06-20       Impact factor: 6.648

7.  Multiphoton fluorescence lifetime imaging of chemotherapy distribution in solid tumors.

Authors:  Marjorie Carlson; Adrienne L Watson; Leah Anderson; David A Largaespada; Paolo P Provenzano
Journal:  J Biomed Opt       Date:  2017-11       Impact factor: 3.170

8.  Bone microenvironment has an influence on the histological response of osteosarcoma to chemotherapy: retrospective analysis and preclinical modeling.

Authors:  Vincent Crenn; Kevin Biteau; Jérôme Amiaud; Clotilde Dumars; Romain Guiho; Luciano Vidal; Louis-Romée Le Nail; Dominique Heymann; Anne Moreau; François Gouin; Françoise Redini
Journal:  Am J Cancer Res       Date:  2017-11-01       Impact factor: 6.166

9.  Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human breast cancer and ovarian cancer xenografts.

Authors:  Beverly A Teicher; Krishna Menon; Enrique Alvarez; Chuan Shih; Margaret M Faul
Journal:  Invest New Drugs       Date:  2002-08       Impact factor: 3.850

10.  The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors.

Authors:  Krupa J Patel; Ian F Tannock
Journal:  BMC Cancer       Date:  2009-10-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.